肝门部胆管癌的移植治疗。

Transplantation for hilar cholangiocarcinoma.

Heimbach Julie K, Haddock Michael G, Alberts Steven R, Nyberg Scott L, Ishitani Michael B, Rosen Charles B, Gores Gregory J

William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN, USA.

Liver Transpl. 2004 Oct;10(10 Suppl 2):S65-8. doi: 10.1002/lt.20266.

Abstract

Patients with primary sclerosing cholangitis (PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20% to 40% at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.

摘要

原发性硬化性胆管炎（PSC）患者发生胆管癌（CCA）的风险为8%至12%。2. 用于检测非整倍体的细胞学技术，如数字图像分析和荧光原位杂交，可提高CCA的检出率。3. CCA切除术后5年生存率为20%至40%。4. 对于无法切除的肝门周围CCA，若肿块病变<3 cm，肝移植术后5年生存率大于80%。5. 肝内CCA患者不符合肝移植条件。